Welcome to Sequence Card of Peptide


Details of CPPsite entry with Sequence RRRRRRRR
Primary information
PEPTIDE SEQUENCERRRRRRRR
CPPsite ID 2012, 2060, 2101, 2131, 2132, 2160, 2292, 2293, 2346, 2489, 2490, 2499, 2501, 2536, 2537, 2538, 2574, 2653, 2658, 2659, 2739, 2746, 2758, 2787, 2788, 2860, 1034, 1237, 1844,
PEPTIDE NAMER9-GFP, P4, GC/R8-Lip, R8, STR-R8, R8, F(SG)4R8, G(SG)4R8, Arg8-ELPBC, Cy3-anti-miRNA/R8, Cy3-siRNA/R8, R8-lipo, R8, R8-GALA-liposome-IgG, R8-GALA-liposome, R8-liposome, R8-lip, Cyt c-ss-R8, M Peptide 8F-L, M Peptide 14F-L, R8, Polyguanidine comparators 1, R8, l-R8-C6-NP, L-R8-INS-NP, R8, R8, R8, R8
CHIRALITYL, L, L, L, L, L, L, L, L, L, L, L, Modified, L, L, L, L, L, L, L, L, L, L, L, L, L, L, L, L
LINEAR/CYCLICLinear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear
SOURCESynthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic
CATEGORYCationic, Amphipathic, NA, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic
SUB CELLULAR LOCALIZATIONCytoplasm, Nucleus, NA, Cytoplasm, Cytoplasm, Cytoplasm, NA, NA, NA, Cytoplasm, Cytoplasm, Cytoplasm, Cytoplasm, Cytosol, Cytosol, Cytosol, Cytosol, Nucleus, NA, NA, Vesicles, Cytoplasm, Cytoplasm, NA, NA, NA, Cytoplasm and nucleus, Unknown, Cytoplasm and nucleus at 4 degrre while in vesicle at 37 degree
N-TERMINAL MODIFICATIONFree, NA, Stearylation, Acetylation, Stearylation, Acetylation, Acetylation, Acetylation, Conjugation with ELPBC, Conjugated with Cy3-anti-miRNA, Conjugated with Cy3-siRNA, Free, Conjugation with Ahx, Conjugation with rhodamine via DOPE, Conjugation with rhodamine via DOPE, Conjugation with rhodamine via DOPE, Free, Conjugated to Radiolabeled cytochrome c with disulphide linkage, Conjugation with HIV inhibiting peptide, Conjugation with HIV inhibiting peptide, NA, Conjugation with 5(6)-Carboxyfluorescein, Conjugation with FITC, Free, Free, Free, Conjugation with fluorescein with 6-aminohexanoic acid (Ahx) spacer, Conjugation with fluorescein, Free
C-TERMINAL MODIFICATIONFree, Free, Free, Amidation, Amidation, Amidation, Amidation, Amidation, Free, NA, NA, Conjugation with liposome, Amidation, Conjugation with GALA-liposome-IgG, Conjugation with GALA-liposome, Conjugation with liposome, Free, NA, Amidation, Amidation, NA, Amidation, NA, Free, Free, Free, Free, Free, Labelled at the C-terminal cysteine using Alexa Fl
CHEMICAL MODIFICATIONNA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, Ahx, 6-aminohexanoic acid, NA, NA, NA, NA, NA, GABA spacer, GABA spacer, NA, NA, NA, NA, NA, NA, NA, NA, NA
UPTAKE EFFICIENCYNA, NA, Highly efficient., NA, Higher than R 8, More than 50% of cells had anti-miRNA/R8 complexes and 68% of anti-miRNA escapes the endosome/lysosome., Higher uptake efficiency for quantum dots, Higher uptake efficiency for quantum dots, Higher uptake, Higher uptake efficiceny, Higher uptake efficiceny, Low uptake efficiency, NA, Higher uptake efficiency, Higher uptake efficiency, Higher uptake efficiency, R8-Lip resulted in a drastic enhancement in the cross-presentation of the OVA antigen compared to K8-Lip, 6-fold higher uptake for Cyt c-ss-R8 compared to unmodified Cyt c was observed, NA, NA, NA, High, NA, NA, NA, NA, High (relative to Tat (49-57)), Unknown, Unknown
PROPOSED UPTAKE MECHANISMEndocytosis (Macropinocytosis), Endocytic pathway, Macropinocytosis, Endocytosis, Endocytosis, Endocytosis, Endocytic pathway, Endocytic pathway, NA, Endocytosis-mediated cellular uptake, Endocytosis-mediated cellular uptake, Energy-dependent properties of integrin receptor mediated endocytosis, NA, Macropinocytosis and classic clathrin-mediated endocytosis, Macropinocytosis and classic clathrin-mediated endocytosis, Macropinocytosis and classic clathrin-mediated endocytosis, NA, NA, NA, NA, NA, Energy-independent internalization, Endocytosis, NA, NA, NA, Probably non-endocytic pathway, Unknown, Unknown
INVITRO/INVIVOIn vivo, In vitro, In vitro and in vivo, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro and in vivo, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro and in vivo, In vitro, In vitro and in vivo, In vitro, In vitro, In vitro and in vivo, In vitro, In vitro, In vitro
CELL LINENA, 293T and HeLa, JAWSII cells, CHO-K1 cells, HeLa, CHO-K1 cells, HeLa, Glioblastoma U251, HeLa, KG1a cells, HeLa, KG1a cells, HeLa, U251 cell line, U251 cell line, Murine glioma cells (C6),bEnd.3 cells and HeLa, HeLa and CHO cells, HeLa cells, HeLa cells, HeLa cells, Bone marrow dendritic cells, HEK293 cells and HeLa cells, HeLa, A549 and CHO-K1, HeLa, A549 and CHO-K1, HeLa cells, MCF-7 cells, HepG2 cells, Caco-2 cells, Caco-2 cells, HUVEC and A549 cells, Jurkat, HeLa, KG1a cells
In VIVO MODELSynechocystis sp. PCC 6803, Synechococcus elongatus PCC 7942, NA, C57BL/6 (H-2b) female mice, NA, NA, NA, NA, NA, NA, NA, NA, Balb/c mice, NA, NA, NA, NA, NA, NA, NA, NA, Female Kunming (KM) mice, NA, Male BALB/cA nude mice and Kunming (KM) mice, NA, NA, A549 xenografts bearing mice and U87 xenografts bearing mice, NA, NA, NA
CARGOProtein (eGFP), Nucleic acid (Plasmid DNA), Protein [GC (-galactosylceramide), ovalbumin], Nucleic acid (GAPDH siRNA), Nucleic acid (GAPDH siRNA), Nucleic acid (siRNA and miRNA), Fluorophore (Alexa488), Protein (bovine serum albumin) and Nanoparticle (quantum dots), Fluorophore (Alexa488), Protein (bovine serum albumin) and Nanoparticle (quantum dots), Peptide (BH3 peptide drug and ELPBC), Nucleic acid (Cy3-labeled anti-miRNA), Nucleic acid (Cy3-labeled anti-miRNA), Nanoparticle (CFPE-labeled liposomes), Dinuclear ruthenium(II) polypyridyl complex, Nanoparticle (Liposome), Protein (IgG), Nanoparticle (Liposome), Nanoparticle (Liposome), Nanoparticle (Liposomes), Protein (Cyt C protein), Peptide (HIV inhibiting peptide), Peptide (HIV inhibiting peptide), Fluorophore (FITC), Fluorophore [5(6)-Carboxyfluorescein (CF)], Nanoparticle (Liposomes), Nanoparticle (Couramin-6 loaded nanoparticle), Nanoparticle (Insulin loaded nanoparticle), Nanoparticle (PEG-PCL), Fluorophore (fluorescein), Fluorophore (fluorescein), Fluorophore (Alexa FI)
PMID23497160, 23281275, 23860186, 25193363, 25193363, 24969623, 25108152, 25108152, 24611762, 24969623, 24969623, 24651033, 25265566, 25546552, 25546552, 25546552, 24901376, 22225540, 22277590, 22277590, 22824782, 22828784, 23031530, 23538098, 23538098, 25448586, 11087855, 21359136, 17217340
PATENTUnknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, US 6593292, Unknown, Unknown
Tertiary Structure
(Technique)		2012 (PEPstrMOD), 2060 (PEPstrMOD), 2101 (PEPstrMOD), 2131 (PEPstrMOD), 2132 (PEPstrMOD), 2160 (PEPstrMOD), 2292 (PEPstrMOD), 2293 (PEPstrMOD), 2346 (PEPstrMOD), 2489 (PEPstrMOD), 2490 (PEPstrMOD), 2499 (PEPstrMOD), 2501 (PEPstrMOD), 2536 (PEPstrMOD), 2537 (PEPstrMOD), 2538 (PEPstrMOD), 2574 (PEPstrMOD), 2653 (PEPstrMOD), 2658 (PEPstrMOD), 2659 (PEPstrMOD), 2739 (PEPstrMOD), 2746 (PEPstrMOD), 2758 (PEPstrMOD), 2787 (PEPstrMOD), 2788 (PEPstrMOD), 2860 (PEPstrMOD), 1034 (PEPstrMOD), 1237 (PEPstrMOD), 1844 (PEPstrMOD),